Kukje Pharma Co., Ltd. (KRX:002720)
South Korea · Delayed Price · Currency is KRW 4,570.00
+80.00 (1.78%)
Feb 19, 2026, 10:40 AM KST
Kukje Pharma Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Net Income | 7,137 | 5,205 | -8,415 | 3,557 | -1,559 | 2,203 |
Depreciation & Amortization | 3,198 | 3,203 | 4,204 | 4,488 | 4,419 | 3,626 |
Asset Writedown & Restructuring Costs | 36.13 | 30.13 | 1,874 | 502.66 | - | - |
Loss (Gain) From Sale of Investments | 182 | 180.1 | -22.11 | 16.73 | -13.21 | -149.32 |
Loss (Gain) on Equity Investments | - | - | - | -23.21 | 72.91 | 13.43 |
Provision & Write-off of Bad Debts | 15.12 | 349.37 | -1,249 | -1,313 | -1,288 | 5,518 |
Other Operating Activities | 3,877 | 3,111 | 1,755 | 3,550 | 2,369 | 2,826 |
Change in Accounts Receivable | -5,592 | -2,334 | 565.75 | 4,648 | 4,595 | 4,241 |
Change in Inventory | -2,860 | -949.39 | 1,290 | -4,789 | 3,261 | -5,526 |
Change in Accounts Payable | 8,339 | -4,396 | 11,579 | 711.15 | 933.17 | -4,706 |
Change in Other Net Operating Assets | -3,384 | -458.16 | -8,006 | -4,845 | -3,192 | -2,947 |
Operating Cash Flow | 10,948 | 3,940 | 3,575 | 6,504 | 9,597 | 5,100 |
Operating Cash Flow Growth | 189.79% | 10.20% | -45.03% | -32.23% | 88.18% | 41.52% |
Capital Expenditures | -1,524 | -2,911 | -1,046 | -1,259 | -1,892 | -11,600 |
Sale of Property, Plant & Equipment | 44.1 | 110.35 | 305.74 | 81.44 | 23.36 | 890.02 |
Sale (Purchase) of Intangibles | -5.73 | -5.73 | - | -18 | -68.5 | - |
Investment in Securities | 68.3 | -1,746 | 190 | - | -1,361 | -2,202 |
Other Investing Activities | -321.15 | -207.63 | -624.89 | -151.54 | -83.05 | 3,931 |
Investing Cash Flow | -1,739 | -4,760 | -1,175 | -1,347 | -3,382 | -8,981 |
Short-Term Debt Issued | - | 10,500 | 7,900 | - | - | 5,351 |
Long-Term Debt Issued | - | - | - | - | - | 2,000 |
Total Debt Issued | 3,000 | 10,500 | 7,900 | - | - | 7,351 |
Short-Term Debt Repaid | - | -11,500 | -4,900 | -7,000 | -2,000 | -6,410 |
Long-Term Debt Repaid | - | -197.65 | -358.95 | -433.03 | -388.36 | -319.13 |
Total Debt Repaid | -2,180 | -11,698 | -5,259 | -7,433 | -2,388 | -6,729 |
Net Debt Issued (Repaid) | 819.59 | -1,198 | 2,641 | -7,433 | -2,388 | 621.95 |
Repurchase of Common Stock | - | - | -31.07 | -40.62 | -45.54 | - |
Dividends Paid | -610.88 | - | - | - | - | - |
Other Financing Activities | 0 | 0 | 0 | 0 | 0 | 0 |
Financing Cash Flow | 208.72 | -1,198 | 2,610 | -7,474 | -2,434 | 621.95 |
Foreign Exchange Rate Adjustments | 58.63 | 105.87 | 40.82 | -10.38 | 71.65 | -176.3 |
Miscellaneous Cash Flow Adjustments | -0 | - | - | - | - | - |
Net Cash Flow | 9,477 | -1,911 | 5,051 | -2,327 | 3,853 | -3,435 |
Free Cash Flow | 9,424 | 1,029 | 2,529 | 5,245 | 7,705 | -6,500 |
Free Cash Flow Growth | 740.99% | -59.32% | -51.78% | -31.93% | - | - |
Free Cash Flow Margin | 5.42% | 0.66% | 1.87% | 4.14% | 6.43% | -4.98% |
Free Cash Flow Per Share | 462.63 | 50.53 | 124.88 | 258.88 | 380.18 | -320.63 |
Cash Interest Paid | 980.99 | 1,220 | 1,418 | 1,003 | 722.5 | 734.31 |
Cash Income Tax Paid | 1,690 | 1,562 | 2,269 | -559.71 | 2,491 | 4,406 |
Levered Free Cash Flow | 6,430 | -3,135 | 8,550 | 3,504 | 5,485 | -4,106 |
Unlevered Free Cash Flow | 7,031 | -2,381 | 9,450 | 4,129 | 5,920 | -3,700 |
Change in Working Capital | -3,497 | -8,138 | 5,429 | -4,274 | 5,597 | -8,937 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.